Highlights from ASCO GU 2018

ASCO GU 2018: Does Treatment Approach for Small Renal Masses Affect Survival in Patients 70 Years Old?

San Francisco, CA (UroToday.com) With the advent of modern imaging techniques, small renal masses are being diagnosed more frequently. Many of these masses are benign, and those that are malignant are often low grade and rarely affect survival. Surveillance is more commonly being advocated as an option for these masses. This study elucidates survival following different treatment approaches.

ASCO GU 2018: Outcomes and Patterns of Disease Progression in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab

San Francisco, CA (UroToday.com)
Background:
Nivolumab (nivo) has been approved for the treatment of refractory metastatic renal cell carcinoma (mRCC). Data regarding the characteristics and outcomes of patients who progress on nivo are lacking.

ASCO GU 2018: The Impact of Facility Case Volume on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in The Targeted Therapy Era

San Francisco, CA (UroToday.com) Prognosis of metastatic renal cell carcinoma (mRCC) has significantly improved in the targeted therapy era. Novel therapies continue to be developed for mRCC, making the management much more nuanced.

ASCO GU 2018: Impact of Intravenous Acetaminophen on Outcomes following Radical Nephrectomy

San Francisco, CA (UroToday.com)
Background:
Intravenous acetaminophen (IVA) was approved for use in the US for moderate to severe pain in 2010. The role of postoperative IVA following radical nephrectomy (RN) is of particular interest given the potential nephrotoxic and bleeding risks associated with other non-opioid alternatives, such as parenteral non-steroidal anti-inflammatory drugs. However, given the relatively high cost of IVA versus other pain medications, the benefit of IVA in the postoperative period is unclear. Therefore, the authors sought to determine if the use of postoperative IVA is associated with improved outcomes following RN.

ASCO GU 2018: Defining Individual Recurrence Risk Following Surgery for High Risk Non-Metastatic Renal Cell Carcinoma

San Francisco, CA (UroToday.com) Current models to estimate renal cell carcinoma (RCC) recurrence risk following surgery are derived from populations containing primarily low-risk patients. The objective of this study was to evaluate risk factors for recurrence among high risk non-metastatic RCC patients following attempted curative surgery.

ASCO GU 2018: Utilization and Survival Implications of a Delayed Approach to Targeted Therapy for Metastatic Renal Cell Carcinoma: A Nationwide Cancer Registry Study

San Francisco, CA (UroToday.com) Targeted therapy (TT) is the first-line option for metastatic renal cell carcinoma (mRCC). While it does provide survival benefit, it is not curative, and all patients eventually progress. It is associated with a high-cost and has known, sometimes significant, adverse events.

ASCO GU 2018: Imaging Modalities Used for Follow-Up of Localized Renal Cell Carcinoma and Subsequent Effect on Overall Survival after Recurrence: RECUR-Database Analysis

San Francisco, CA (UroToday.com)
Background:
Cross-sectional imaging (CSI) has emerged as the preferred imaging modality for staging and follow-up (FU). Moreover, the 2017 EAU renal cell carcinoma (RCC) guidelines discourage the use of Chest X-Ray (CXR). In an international database (RECUR) data were collected to compare imaging modalities in contemporary FU, and to explore if more frequent use of CSI translates into improved overall survival (OS) after recurrence.

Page 3 of 33

Stay Connected

Login